CTXR · XBRL financial data

Citius Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CTXR's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024†Sep 30, 2024	FY 2025Sep 30, 2025
Research and development	8,813	12,241	17,655	14,820	11,907	9,156
General and administrative	8,095	9,836	11,755	15,296	18,249	18,533
Total operating expenses	17,711	23,532	33,316	36,732	41,996	38,526
Other operating income (expense)	—	477	251	—	—	—
Operating income (loss)	(17,711)	(23,532)	(33,316)	(36,732)	(41,996)	(38,526)
Interest income	68	262	251	1,179	758	110
Interest expense	16	11	—	—	—	268
Income tax expense (benefit)	1	1	576	576	576	1,057
Net income (loss)	(17,548)	(23,054)	(33,641)	(32,543)	—	—
Earnings per share, basic USD per share	—	(0.23)	(0.23)	(5.57)	(5.97)	(3.38)
Earnings per share, diluted USD per share	—	(0.23)	(0.23)	(5.57)	(5.97)	(3.38)
Weighted average shares, basic thousands of shares	—	108,599	146,082	151,295	6,727	11,065
Weighted average shares, diluted thousands of shares	—	108,599	146,082	151,295	6,727	11,065

† Share count changed about 1/21 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CTXR's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024†Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	13,860	70,073	41,712	26,481	3,252	4,252
Inventory	—	—	—	—	8,269	22,287
Total current assets	13,982	72,814	44,564	34,370	14,221	27,934
Property and equipment, net	2	7	4	1	—	—
Right-of-use asset	986	823	646	454	246	819
Goodwill	9,347	9,347	9,347	9,347	9,347	9,347
Total assets	43,774	142,429	113,999	103,611	116,652	130,938
Accounts payable	1,856	1,277	1,165	2,927	4,927	13,694
Accrued liabilities	164	622	1,405	476	17	4,190
Commercial paper	—	—	—	—	—	300,000
Total current liabilities	4,097	3,982	4,530	5,779	35,815	44,915
Lease liability, non-current	855	678	481	263	21	725
Total liabilities	10,103	9,646	10,573	12,180	42,550	53,410
Accumulated deficit	(70,594)	(96,048)	(129,688)	(162,231)	(201,370)	(238,804)
Total stockholders' equity	33,671	132,182	102,826	90,831	70,077	67,550
Total liabilities and equity	43,774	142,429	113,999	103,611	116,652	130,938
Common shares outstanding (cover page) thousands of shares	55,577	146,030	146,211	158,967	7,727	20,763

† Share count changed about 1/21 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CTXR's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024†Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(17,548)	(23,054)	(33,641)	(32,543)	—	—
Stock-based compensation	803	1,455	3,906	6,617	11,840	10,836
Net cash from operating activities	(16,931)	(24,250)	(28,361)	(29,060)	(28,201)	(26,553)
Purchases of property and equipment	2	7	—	—	—	—
Net cash from investing activities	(2)	(40,007)	—	—	(5,000)	(5,750)
Proceeds from issuing common stock	—	83	—	—	252	32,303
Net cash from financing activities	22,898	120,471	—	13,829	9,972	33,303

† Share count changed about 1/21 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.